Shots:

• Bio-Thera will take care of full development- and commercial supply of BAT2506 out of the manufacturing facilities in Guangzhou- China. Additionally- the agreement will utilize Pharmapark’s local presence- sales- and marketing capabilities in Russia and other CIS countries
• Pharmapark to get exclusive rights to distribute and market the product in Russia and other CIS countries including its filing practices. In Q4’20- Bio-Thera to begin its global P-III trial in PsA patients and will include patients from China- Russia- and many other countries  
• Bio-Thera’s BAT2506 is a mAb while the company plans for regulatory submission with NMPA- EMA and the US FDA in 2023

Ref: Bio-Thera | Image: Pharma World